148 related articles for article (PubMed ID: 21704501)
21. The neuropsychological profiles of young psychosis patients with and without current cannabis use.
Bogaty SER; Crouse JJ; Hickie IB; Hermens DF
Cogn Neuropsychiatry; 2019 Jan; 24(1):40-53. PubMed ID: 30621505
[TBL] [Abstract][Full Text] [Related]
22. The positive link between executive function and lifetime cannabis use in schizophrenia is not explained by current levels of superior social cognition.
Helle S; Løberg EM; Gjestad R; Schnakenberg Martin AM; Lysaker PH
Psychiatry Res; 2017 Apr; 250():92-98. PubMed ID: 28152399
[TBL] [Abstract][Full Text] [Related]
23. The effects of cannabis use on the clinical condition of schizophrenics.
Negrete JC; Knapp WP
NIDA Res Monogr; 1986; 67():321-7. PubMed ID: 3092086
[No Abstract] [Full Text] [Related]
24. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use.
Coulston CM; Perdices M; Tennant CC
Schizophr Res; 2007 Nov; 96(1-3):169-84. PubMed ID: 17826035
[TBL] [Abstract][Full Text] [Related]
25. Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder.
Braga RJ; Burdick KE; Derosse P; Malhotra AK
Psychiatry Res; 2012 Dec; 200(2-3):242-5. PubMed ID: 22818174
[TBL] [Abstract][Full Text] [Related]
26. Influence of cannabis abuse on schizophrenic psychopathology.
Peralta V; Cuesta MJ
Acta Psychiatr Scand; 1992 Feb; 85(2):127-30. PubMed ID: 1543037
[TBL] [Abstract][Full Text] [Related]
27. No additive effect of cannabis on cognition in schizophrenia.
Power BD; Dragovic M; Badcock JC; Morgan VA; Castle D; Jablensky A; Stefanis NC
Schizophr Res; 2015 Oct; 168(1-2):245-51. PubMed ID: 26235754
[TBL] [Abstract][Full Text] [Related]
28. Variable individual sensitivity to cannabis in patients with schizophrenia.
Goldberger C; Dervaux A; Gourion D; Bourdel MC; Lôo H; Laqueille X; Krebs MO
Int J Neuropsychopharmacol; 2010 Oct; 13(9):1145-54. PubMed ID: 20529414
[TBL] [Abstract][Full Text] [Related]
29. Craving in patients with schizophrenia and cannabis use disorders.
Schnell T; Becker T; Thiel MC; Gouzoulis-Mayfrank E
Can J Psychiatry; 2013 Nov; 58(11):646-9. PubMed ID: 24246436
[TBL] [Abstract][Full Text] [Related]
30. Risk-taking in schizophrenia and controls with and without cannabis dependence.
Fischer BA; McMahon RP; Kelly DL; Wehring HJ; Meyer WA; Feldman S; Carpenter WT; Gorelick DA
Schizophr Res; 2015 Feb; 161(2-3):471-7. PubMed ID: 25467541
[TBL] [Abstract][Full Text] [Related]
31. [Review: executive functioning and cannabis use].
Almeida PP; Novaes MA; Bressan RA; Lacerda AL
Braz J Psychiatry; 2008 Mar; 30(1):69-76. PubMed ID: 18373021
[TBL] [Abstract][Full Text] [Related]
32. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study.
van Dijk D; Koeter MW; Hijman R; Kahn RS; van den Brink W
Schizophr Res; 2012 May; 137(1-3):50-7. PubMed ID: 22313726
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal changes in cognition in young adult cannabis users.
Becker MP; Collins PF; Schultz A; Urošević S; Schmaling B; Luciana M
J Clin Exp Neuropsychol; 2018 Aug; 40(6):529-543. PubMed ID: 29058519
[TBL] [Abstract][Full Text] [Related]
34. Nonacute (residual) neuropsychological effects of cannabis use: a qualitative analysis and systematic review.
Gonzalez R; Carey C; Grant I
J Clin Pharmacol; 2002 Nov; 42(S1):48S-57S. PubMed ID: 12412836
[TBL] [Abstract][Full Text] [Related]
35. [Can cannabis use increase the risk for schizophrenic psychoses?].
Bugra H; Rapp C; Studerus E; Aston J; Borgwardt S; Riecher-Rössler A
Fortschr Neurol Psychiatr; 2012 Nov; 80(11):635-43. PubMed ID: 23139065
[TBL] [Abstract][Full Text] [Related]
36. Cognitive Enhancement Therapy in substance misusing schizophrenia: results of an 18-month feasibility trial.
Eack SM; Hogarty SS; Greenwald DP; Litschge MY; McKnight SA; Bangalore SS; Pogue-Geile MF; Keshavan MS; Cornelius JR
Schizophr Res; 2015 Feb; 161(2-3):478-83. PubMed ID: 25510926
[TBL] [Abstract][Full Text] [Related]
37. Effects of Extended Cannabis Abstinence on Cognitive Outcomes in Cannabis Dependent Patients with Schizophrenia vs Non-Psychiatric Controls.
Rabin RA; Barr MS; Goodman MS; Herman Y; Zakzanis KK; Kish SJ; Kiang M; Remington G; George TP
Neuropsychopharmacology; 2017 Oct; 42(11):2259-2271. PubMed ID: 28443616
[TBL] [Abstract][Full Text] [Related]
38. History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders.
Menendez-Miranda I; Garcia-Alvarez L; Garcia-Portilla MP; Gonzalez-Blanco L; Saiz PA; Bobes J
Eur Addict Res; 2019; 25(3):111-118. PubMed ID: 30897572
[TBL] [Abstract][Full Text] [Related]
39. Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients.
Jockers-Scherübl MC; Matthies U; Danker-Hopfe H; Lang UE; Mahlberg R; Hellweg R
J Psychopharmacol; 2003 Dec; 17(4):439-45. PubMed ID: 14870957
[TBL] [Abstract][Full Text] [Related]
40. Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review.
Broyd SJ; van Hell HH; Beale C; Yücel M; Solowij N
Biol Psychiatry; 2016 Apr; 79(7):557-67. PubMed ID: 26858214
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
